AT148002 (ALX Oncology)
Description: A Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS)
Mechanism of Action: ALX148 is a CD47 blocker.
Target Patient Population: High Risk MDS
Study Design: Study Drug will be administered IV every 2 or 4 weeks. Combination drug, Azacitidine given as would Standard of Care.